Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/isrn/volume-2017/8404378/figures/8404378.fig.002a.svgz" name="8404378.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Showing self-report responses by the children to the PedsQL psychosocial domain before and 6 months after the treatment</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/isrn/volume-2017/8404378/figures/8404378.fig.002b.svgz" name="8404378.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Showing proxy-report responses by the parents of all the children to the PedsQL psychosocial domain before and 6 months after the treatment</td></tr></table>

International Scholarly Research Notices

fig2

Figure 2

Figure 2: Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex 